Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma - Recurrence-free Survival in the Intention-to-Treat Population #EBM#Honc#Nivolumab#Ipilimumab#Melanoma#NEJM
Board Certified Internal Medicine Hospitalist, GrepMed Editor in Chief 🇵🇭 🇺🇸 - Sign up for an account to like, bookmark and upload images to contribute to our community platform. Follow us on IG: https://www.instagram.com/grepmed/ | Twitter: https://twitter.com/grepmeded/
